On Invalid Date, Aquestive Therapeutics (NASDAQ: AQST) reported Q4 2023 earnings per share (EPS) of -$0.13, up 40.91% year over year. Total Aquestive Therapeutics earnings for the quarter were -$8.11 million. In the same quarter last year, Aquestive Therapeutics's earnings per share (EPS) was -$0.22.
As of Q1 2024, Aquestive Therapeutics's earnings has grown year over year. Aquestive Therapeutics's earnings in the past year totalled -$7.87 million.
What is AQST's earnings date?
Aquestive Therapeutics's earnings date is Invalid Date. Add AQST to your watchlist to be reminded of AQST's next earnings announcement.
What was AQST's revenue last quarter?
On Invalid Date, Aquestive Therapeutics (NASDAQ: AQST) reported Q4 2023 revenue of $13.21 million up 23.63% year over year. In the same quarter last year, Aquestive Therapeutics's revenue was $10.68 million.
What was AQST's revenue growth in the past year?
As of Q1 2024, Aquestive Therapeutics's revenue has grown 6.09% year over year. This is 3.69 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 9.78%. Aquestive Therapeutics's revenue in the past year totalled $50.58 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.